ERBB2 and non-small cell lung carcinoma: For NSCLC patients, targeted HER2 therapies currently in clinical trials include monoclonal antibodies (trastuzumab and pertuzumab), TKIs (afatinib, pyrotinib, dacomitinib and neratinib), and antibody-drug conjugates (ADCs) (T-DM1, T-DXd).